Abstract
Tepotinib is one of the key drugs for MET exon 14-skipping mutation-positive non-small cell lung cancer (NSCLC). The main adverse event of tepotinib t......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
